nightwatchepilepsy.com 的前十大競爭對手

empatica.com

Lär dig hur Empatica samlar in, använder och skyddar dina personuppgifter. Din integritet är viktig för oss – läs hela vår policy här.

epilepsyfoundation.org.au

Epilepsy affects 1 in 25 Australians. Understanding the condition and knowing how to respond during a seizure can save lives and create safer, more inclusive environments at home, school, work…

epilepsyalarms.co.uk

Take control of your epilepsy with EpiMonitor, your complete companion for life – paired with EmbracePlus, the world’s most advanced medical smartwatch.

epiwatch.com

EpiWatch® is the first and only FDA-cleared seizure detection app for Apple Watch. Detect tonic-clonic seizures, send real-time alerts to caregivers, and reduce the risk of SUDEP. Live more independently with confidence on your wrist.

kempenhaeghe.nl

Kempenhaeghe is het Academisch Centrum voor Epilepsie met de juiste aandacht voor optimale epilepsiezorg. Bezoek website of ☎ (040) 227 97 77

dannydid.org

We work toward advancing public awareness, education and disclosure between medical professionals and families affected by Sudden Unexpected Death in Epilepsy (SUDEP).

epilepsie.nl

Wil je in contact komen met EpilepsieNL? Vind hier ons telefoonnummer, adres en e-mailadres. We staan voor je klaar om je vragen te beantwoorden.

magventure.com

No matter your location, our global service and support team is here for you. See our qualified and professional network of distributors.

electrocore.com

PRESTO demonstrates clinical benefit of gammaCore in the acute treatment of migraine compared to sham Basking Ridge, NJ, September 11, 2017 – electroCore, a neuroscience and technology company dedicated to improving patient outcomes through technological advancement, announced the first results from the PRESTO (The PRospectivE Study of nVNS for the Acute Treatment Of Migraine) clinical trial evaluating the use of gammaCore® (non-invasive vagus nerve stimulator) in migraine at the 18th Congress of the International Headache Society (IHC). Findings from the study “Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Migraine: A Randomized Controlled Trial” (IHC Abstract OC-LB-002) were presented on Saturday, September 9 as a late-breaking oral presentation. “Migraine is the third most common disease in the world,[i] and one of the 10 most disabling diseases, which highlights a need for novel treatment options,” said Dr. Cristina Tassorelli, Director of the Headache Science Centre, National Neurological Institute C. Mondino Foundation;  Professor at the University of Pavia, Pavia, Italy; and principal trial investigator. “The PRESTO data suggests that gammaCore was rapidly effective, well tolerated and practical for the acute treatment of episodic migraine. The data supports the use of gammaCore to successfully treat a migraine, making the device a...